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ORIGINAL ARTICLE
Effects of fluticasone propionate in COPD patients with
bronchial hyperresponsiveness
G T Verhoeven, J P J J Hegmans, P G H Mulder, J M Bogaard, H C Hoogsteden,
J-B Prins
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Background: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids
does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups
of patients with COPD benefit from steroid treatment. A study was undertaken to examine whether
inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a
subgroup of COPD patients with bronchial hyperresponsiveness (BHR).
Methods: Twenty three patients with COPD were studied. Patients had to be persistent current smokers
between 40 and 70 years of age. Non-specific BHR was defined as a PC20 for histamine of <8 mg/
ml. Patients received either 2 × 500 µg FP or placebo for 6 months. Expiratory volumes were measured
at monthly visits, BHR was determined at the start of the study and after 3 and 6 months, and bronchial
biopsy specimens were taken at the start and after 6 months of treatment. Biopsy specimens from
asymptomatic smokers served as controls.
Results: In contrast to asthma, indices of BHR were not significantly influenced by treatment with FP.
Forced expiratory volume in 1 second (FEV1) showed a steep decline in the placebo group but
remained stable in patients treated with FP. FEV1/FVC, and maximal expiratory flows at 50% and 25%
FVC (MEF50, MEF25) were significantly increased in the FP treated patients compared with the placebo
group. Biopsy specimens were analysed for the presence of CD3+, CD4+, CD8+, MBP+, CD15+,
CD68+, CD1a, and tryptase cells. FP treatment resulted in marginal reductions in these indices of
inflammation.
Conclusion: In patients with COPD and BHR, FP has a positive effect on indices of lung function com-
pared with placebo. Bronchial inflammation analysed in bronchial biopsy specimens is only marginally
reduced.
Chronic obstructive pulmonary disease (COPD) is char-acterised by reduced maximum expiratory flow andslow forced emptying of the lungs. About 15% of smok-
ers develop COPD. The airways are markedly inflamed, but the
predominant types of inflammatory cells and the main
anatomical site of the lesions appear to differ from those in
asthma.1–3
Inhaled corticosteroids are used in the treatment of asthma,
but the beneficial effects of steroid treatment in COPD are
debatable. The improvements in lung function parameters,
which are characteristic of steroid treatment in asthma, have
not been unequivocally found in patients with COPD.4–7 It has
been postulated that, if steroids are important in the
treatment of COPD, they act via downregulation of cytokine
and adhesion molecule expression with a consequent reduc-
tion in cell migration and activation.8 To date, only a limited
number of studies have examined the effect of steroid
treatment on inflammation in COPD.
Approximately 25% of patients with stable COPD could,
however, benefit from continuous steroid treatment.9 It has
been suggested that inhaled corticosteroids are more likely to
have beneficial effects in patients with COPD when features of
asthma are present.10 It has recently been reported that pred-
nisolone has a beneficial effect in patients with COPD who
have increased numbers of sputum eosinophils.11 In a large
multicentre trial in patients with respiratory symptoms, the
effect of an inhaled steroid on the course of forced expiratory
volume in 1 second (FEV1) was found to be most prominent in
those with more severe bronchial hyperresponsiveness
(BHR).12 BHR is usually seen as a distinguishing characteristic
of asthma, but is found surprisingly often in patients with
COPD and in smokers.13 14 The features of BHR, however, differ
between asthma and COPD. In COPD the presence of BHR is
associated with more severe disease, leading to an even more
accelerated decline in lung function (FEV1) resulting in
reduced life expectancy.15–18 It could be an indicator of a more
serious and/or a different inflammatory process in the airways
of these patients with COPD.19–21
A study was therefore undertaken to determine whether
patients with COPD and BHR would benefit from treatment
with fluticasone propionate (FP), an inhaled steroid.
METHODS
Patients
Twenty three patients with COPD were selected according to
generally accepted criteria (chronic productive cough, FEV1
<70% of predicted normal value, FEV1 reversibility of <10%
predicted after 750 µg terbutaline administered by metered
dose inhalation, negative serological examination (Phadiatop
test), and negative skin prick tests for standard inhaled
allergens).22 Patients with an FEV1/inspiratory vital capacity
(IVC) ratio of <0.70 were also included, provided their total
lung capacity (TLC) was greater than the predicted value +
1.64SD. Reference values were obtained from ECGS
standards.23 Participants had to be current and persistent
smokers aged 40–70 years.
Non-specific BHR was defined as a concentration of
histamine provoking a fall in FEV1 of 20% or more (PC20 hista-
mine) of <8 mg/ml. FEV1 had to be >1.2 l to ensure complete
safety in view of the bronchial provocation tests.
The characteristics of the patients are listed in table 1.
Subjects were excluded if they had a history of asthma
characterised by attacks of dyspnoea, chest tightness or
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wheezing, respiratory tract infection in the 4 weeks preceding
the first visit, or were suffering from serious or unstable con-
comitant disease.
Eligible patients using anti-inflammatory treatment includ-
ing non-steroidal anti-inflammatory drugs were asked to
refrain from oral prescriptions for at least 3 months and from
inhaled corticosteroids, sodium cromoglycate, or nedocromil
sodium for at least 6 weeks before the start of the study. Long
acting β2 agonists, xanthine derivatives, and antihistamine
drugs also had to be stopped at least 6 weeks before the start
of the study. Patients whose symptoms or lung function dete-
riorated after discontinuation of drug treatment were
excluded from the study.
Six asymptomatic smokers with a normal maximal expira-
tory flow-volume (MEFV) curve, PC20 histamine >8 mg/ml,
and absence of allergy (negative Phadiatop test) served as
controls (table 1).
The hospital medical ethics committee approved the study.
Written informed consent was obtained from all participants.
Study design
The study was double blind and placebo controlled with a
treatment period of 6 months. The design is schematically
presented in fig 1.
During the 2 week run in period, subjects underwent lung
function tests. Eligible patients were randomly allocated to
either the treatment group (n=10) who received 500 µg FP
twice daily via a Diskhaler, or to the placebo group (n=13)
who received their prescription via a similar device. Salbuta-
mol via Diskhaler was given as rescue medication. Inhalation
of ipratropium bromide was allowed at a constant dosage.
Bronchial biopsy specimens were collected at the start of the
treatment period and after 6 months. The participants visited
the outpatient clinic every 4 weeks when their used and
unused medication from the preceding period was collected
and the MEFV curve before and after inhalation of 750 µg
terbutaline was determined. BHR was tested with metha-
choline at the start of the study, at 3 months, and at the end of
the treatment period.
Lung function tests
Spirometric parameters (total lung capacity (TLC), functional
residual capacity (FRC), IVC, FEV1) were measured at baseline
using the closed circuit helium wash-in method. At the start
of the study and at each 4 week visit MEFV curves were
recorded using a heated pneumotachometer (Jaeger, Wurz-
burg, Germany). From the MEFV curve the forced vital capac-
ity (FVC), peak expiratory flow (PEF), and maximal expira-
tory flows at 50% and 25% of FVC (MEF50, MEF25) were
derived. All MEFV curves were recorded at the same time of
the day. Patients were instructed not to take any bronchodila-
tors for at least 8 hours before lung function tests.
Histamine and methacholine provocation tests were per-
formed using the 2 minute tidal breathing method. Histamine
was used to determine PC20 (inclusion criterion), while
methacholine was used to establish a full dose-response curve.
Solutions of histamine sulphate and acetyl-β-methylcholine
bromide were prepared, stored at 4°C, and used at room tem-
perature. Aerosols were generated by a nebuliser (Model 646;
DeVilbiss Co, Somerset, PA, USA) (measured output 0.13 ml/
min) and inhaled by tidal breathing over a 2 minute period at
5 minute intervals. After inhalation of an isotonic saline solu-
tion, doubling concentrations (0.03–256 mg/ml) of histamine
or methacholine were administered. The response to metha-
choline or histamine was measured as the change in FEV1
expressed as a percentage of the initial value. FEV1 was derived
from the pneumotachograph readings and PC20 was calculated
from these data. Histamine provocation tests were interrupted
if a 20% fall in FEV1 was achieved at a histamine concentration
of<8 mg/ml. Methacholine tests were interrupted if the FEV1
fell by more than 60%, or if unpleasant side effects occurred.
After the test the patient inhaled a bronchodilator to restore
the FEV1 to the initial value.
From the methacholine provocation tests the log2 concen-
tration and the measured percentage changes in FEV1 were
imported to a computer program that fitted a sigmoid
function (cumulative Gaussian distribution) to the data.24
Reactivity (slope of the curve), plateau values (maximal
bronchoconstriction), and EC50 (concentration of the stimulus
causing 50% of maximal bronchoconstriction) were taken
from this model fit.
After an overnight fast, blood was drawn for measurement
of circulating cortisol levels early in the morning before the
lung function tests. The concentration of cortisol was
determined using kits supplied by Diagnostics Products
Corporation (Los Angeles, California, USA).25
Bronchoscopic examination
The procedure was carried out essentially as described in the
ATS guidelines.26 At the start of the procedure the patient was
Table 1 Mean (range) characteristics of study subjects
Asymptomatic
smokers (n=6)
Fluticasone
propionate (n=10) Placebo (n=13)
M/F 3/3 8/2 11/2
Age (years) 44 (32–56) 54 (42–65) 56 (42–67)
No cigarettes/day 21 (13–40) 15 (6–30) 16 (6–30)
Pack years 23 (6–82) 25 (5–50) 26 11–50)
Serum IgE (U/l) ND 72 (12–172) 81 (7–405)
Blood eosinophils (×103/l) ND 163 (20–440) 195 (24–360)
FEV1 (l) 2.8 (2.1–3.5)* 2.1 (1.5–3.1) 2.0 (1.3–2.9)
FEV1 (% predicted) 93 (79–101)† 66 (55–93)‡ 61 (34–72)
Reversibility (% predicted) 4.0 (0–8) 5.3 (0–9.8) 5.6 (0–9.9)
FEV1/FVC 0.79 (0.76–0.84) 0.56 (0.48–0.60) 0.56 (0.46–0.61)
PC20 histamine (mg/ml) >8 2.6 (0.1–8.0) 0.8 (0.1–2.3)
PC20 methacholine (mg/ml) ND 6.3 (0.7–17.4) 2.6 (0.4–16.5)
FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; PC20=concentration provoking a fall
in FEV1 of 20% or more; ND = not done.
*p=0.02, †p=0.01 asymptomatic smokers v COPD patients.
‡One patient with FEV1 of 93% predicted could be included because his FEV1/FVC was 0.49.
Figure 1 Design of study.
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given 0.5 mg atropine intramuscularly. A pulse oximeter was
applied to a fingertip to monitor pulse rate and oxygen satura-
tion. The mouth and pharynx were anaesthetised with
lidocaine spray, and the vocal cords, trachea and bronchial tree
were anaesthetised with aerosolised oxybuprocaine solution
(5 mg/ml) up to a maximum of 20 ml. Bronchoscopic
examination was performed with an Olympus BF 1T10 bron-
choscope. At least six biopsy specimens were taken from the
subcarinae of both the right and left upper and lower lobes
using a fenestrated forceps (FB-18C or FB-20C). Sedative
drugs and/or oxygen were administered if needed.
Processing of bronchial biopsy specimens
Bronchial biopsy specimens were snap frozen in Tissue-Tek II
OCT embedding medium (Miles, Naperville, Illinois, USA) in
liquid nitrogen within 10 minutes of collection and stored at
–80°C. Once all the biopsy specimens had been collected, 6 µm
serial tissue sections were cut on an HM-560 cryostat
(Microm, Heidelberg, Germany). At least two sections 120 µm
apart from one biopsy specimen were placed on a poly-L-lysine
coated microscopic slide (Sigma Diagnostics, St Louis, MO,
USA). The sections were air dried for 30 minutes and stored at
–80°C until use. Immunostaining was carried out with αCD3
(UCHT1), αCD4 (MT310), αCD8 (DK25), and αCD25 (ACT-1)
(Becton Dickinson, San Jose, CA, USA); αCD1a (NA1/34),
αCD15 (C3D-1), αCD68 (EMB11), and αMBP (BMK13)
(Dako, Glostrup, Denmark); α-tryptase (Chemicon
Brunschwig Chemie, Temecula, CA, USA); αEG2 (Pharmacia).
Binding of the antibodies was detected by the immunoalka-
line phosphatase anti-alkaline phosphatase (APAAP) method.
Sections were fixed in acetone for 10 minutes at room
temperature, rinsed in phosphate buffered saline (PBS), pH
7.2, and placed in a semi-automatic stainer (Shandon,
Pittsburgh, PA, USA). The slides were sequentially incubated
with 2% bovine serum albumin (BSA) in PBS for 10 minutes,
with 10% normal rabbit serum in PBS (Central Laboratory of
the Netherlands Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands) for 10 minutes, and then with
the appropriate monoclonal antibodies for 60 minutes at room
temperature. The sections were then rinsed twice in PBS for 5
minutes and incubated with a rabbit anti-mouse (RαM)
(1:50) immunoglobulin serum for 30 minutes. The slides were
rinsed twice in PBS, incubated with APAAP (1:50) (Dako,
Glostrup, Denmark) for 30 minutes at 20°C, rinsed in PBS and
Tris buffer (pH 8.0), and incubated for 30 minutes with New
Fuchsin substrate (Chroma, Stuttgart, Germany) as chro-
mogen. Sections were counterstained with Mayer’s haema-
toxylin.
Immunostained sections were analysed with an image
analysis system consisting of a 3CCD (charge coupled device)
colour video camera (DXC-950, Sony, Tokyo, Japan) mounted
on a Leica DM RBE microscope (Leica, Rijswijk, The
Netherlands) and connected to a Matrox Meteor frame grab-
ber in a Pentium 200 MHz personal computer. Illumination
was provided by a halogen light source connected to a
stabilised adjustable power supply (12V/100W). Since the
emission of light sources and the noise and sensitivity of CCD
cameras are known to vary with temperature, all hardware
was allowed a 1 hour warming up period to minimise
unwanted thermal effects. Images were taken at 10×10 mag-
nification.
The image analysis software consisted of the QWin Stand-
ard software (Leica) running under Microsoft Windows envi-
ronment. Images were analysed by drawing a line with the
cursor along the reticular basement membrane. The program
was set to calculate the area below the indicated reticular
basement membrane up to 100 µm deep into the lamina pro-
pria. The outer perimeter of the intact epithelium was then
drawn. This enabled the total area of epithelium to be
calculated. Detection of the colour of interest was performed
by setting thresholds for hue, saturation, and intensity. During
the image analysis procedure, hue, saturation and intensity
were set for each immunohistochemical stain and kept
constant during the analysis of the entire study population for
that particular stain. This approach allowed densitometric
analysis to be undertaken, but made comparison between
marker molecules impossible since density is not only
dependent on the level of expression of a specific protein but
is also influenced by the efficiency and intensity of a particu-
lar immunostain.
Immunohistochemical data are presented as the ratio of
immunostained areas and the total area of either the
epithelium or the lamina propria. If the total area studied was
less than 100 000 µm2 for a given subject, this subject was
excluded from further analysis of that particular inflamma-
tory marker.
Statistical analysis
Results are expressed as mean (SD) unless otherwise
indicated. Differences between groups in the effect of
treatment and its interaction with time were analysed using
the unpaired Student’s t test or the Mann-Whitney U test
where appropriate. Paired data were tested for significance
with the paired Student’s t test or, after log transformation, the
Wilcoxon matched pairs test where appropriate. A rmANOVA
was performed for the dependent variables FEV1 (as percent-
age predicted), FVC, FEV1/FVC, PEF, MEF50, and MEF25 after
log transformation. From each of these variables, one baseline
measurement and six measurements taken during the
treatment period were available. The results were adjusted for
the baseline measurement of the outcome variable considered.
In the rmANOVA model the independent variables were time
(a within subject categorical factor with six levels), treatment
(a between subjects factor with two levels), and the baseline
measurement of the outcome variable considered as a
Figure 2 Mean PC20 methacholine during treatment period of 6
months with either fluticasone propionate (closed symbols) or
placebo (open symbols); p>0.05 (ANOVA).
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Figure 3 Fitted methacholine dose-response curves showing mean
values for fluticasone propionate treated patients at the start of
treatment (continuous line), after 3 months of treatment (dotted line),
and at the end of the 6 month treatment period (dashed line).
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between subjects continuous and constant variable. The
within subject residual covariance structure is assumed to be
of “compound symmetry”. A p value of <0.05 was considered
significant.
RESULTS
Patients
Participants in the study had mild to moderate COPD accord-
ing to ERS criteria and moderately to severe BHR. At baseline
there were no significant differences between the FP and pla-
cebo groups. Asymptomatic smokers and patients with COPD
had significantly different FEV1 and FEV1/FVC (table 1).
Compliance with study medication was good. The percent-
age of returned used blister packs did not differ between the
groups (92.5% in the FP group and 90.7% in the placebo
group).
During the treatment period no subjects dropped out of the
study. Periodically, several participants noticed worsening of
disease related symptoms such as coughing and production of
sputum. In all cases these symptoms could be resolved with
rescue medication while not violating the inclusion criteria.
Adverse events were reported 25 times in the FP treated group
and 28 times in the placebo group (p>0.05). Events relating to
airways disease and/or study medication were reported more
often by patients receiving placebo than by FP treated patients
(18 v 7, p=0.02), and included candidiasis of the mouth (in
the FP treated group), stomatitis, throat pain, irritation of the
pharynx, upper respiratory tract infection, acute bronchitis
without decrease in FEV1, and mild increase in airways
obstruction.
The use of rescue medication did not differ between the two
groups. The mean numbers of salbutamol dosages used in the
FP and placebo groups were 32.5 (27.0) and 40.4 (42.7) per
month, respectively (p>0.05), and the mean numbers of ipra-
tropium bromide dosages used were 2.2 (4.7) and 9.6 (3.0) per
month, respectively.
At the start of the study mean circulating cortisol levels
were 360.9 (112) nM/l and 335 (87) nM/l in the FP and
placebo groups, respectively. After 6 months the mean levels
were 414.6 (156) nM/l and 430 (104) nM/l. The levels were not
significantly different between groups at a given time point,
nor were they significantly different between time points.
Lung function
During the 6 month treatment period the mean PC20
methacholine increased in the FP treated patients relative to
the placebo group (fig 2), but this increase was not statistically
significant. No significant changes in reactivity, maximal
bronchial constriction (plateau), and EC50 were detected (fig
3). There were no significant treatment × time interactions
(table 2); treatment effects were therefore not significantly
modified in time so we can assume a treatment effect that was
constant throughout time. These treatment effects (FP minus
placebo) are presented in table 3.
Changes in mean FEV1 after bronchodilation are shown in
fig 4A. A significant decline in FEV1 was seen in the placebo
group while FEV1 in the FP treated group remained almost
unchanged. The mean decline in FEV1 in the placebo group
compared with the FP treated patients was 6.92% predicted
before bronchodilation (p=0.027) and 7.97% predicted after
bronchodilation (p=0.002). The course of the prebronchodila-
tor and postbronchodilator FEV1 was significantly different
between the two treatment groups (prebronchodilator,
p=0.015; postbronchodilator, p=0.0002 (rmANOVA); fig 4B).
The starting values were taken as covariants for the rmANOVA
tests. The FEV1/FVC ratio (prebronchodilator) showed a simi-
lar pattern of change (mean difference 0.065, p=0.024,
rmANOVA). There were significant changes in MEF50 from the
second month of treatment (0.29 (0.07) l; p=0.002) and in
MEF25 from the third month of treatment (0.32 (0.09) l;
p=0.008, fig 5A, B). Neither FVC nor PEF were affected and
remained unchanged in both groups.
Table 2 Treatment × time interactions
Outcome variable p value
FEV1 after 0.4906
FEV1 before 0.7286
FEV1 (% pred) after 0.4741
FEV1 (% pred) before 0.7772
MEF25 0.2705
MEF50 0.1500
FEV/FVC 0.0720
log2 PC20 0.5538
FEV1=forced expiratory volume in 1 second; FVC=forced vital
capacity; MEF25, MEF50=maximal expiratory flow at 25% and 50% of
FVC; PC20=concentration provoking a fall in FEV1 of 20% or more.
Table 3 Treatment effects (fluticasone propionate v
placebo)
Outcome variable
Point
estimate 95% CI p value
FEV1 after 0.250 0.113 to 0.386 0.0011
FEV1 before 0.218 0.038 to 0.398 0.0202
FEV1 (% pred) after 7.92 3.34 to 12.51 0.0018
FEV1 (% pred) before 6.81 0.86 to 12.75 0.0269
MEF25 7.36 2.15 to 12.58 0.0080
MEF50 7.54 3.10 to 11.97 0.0020
FEV/FVC 5.34 0.77 to 9.91 0.0243
log2 PC20 0.872 –0.891 to 2.64 0.3143
FEV1=forced expiratory volume in 1 second; FVC=forced vital
capacity; MEF25, MEF50=maximal expiratory flow at 25% and 50% of
FVC; PC20=concentration provoking a fall in FEV1 of 20% or more.
Figure 4 (A) Change in forced expiratory volume in 1 second (FEV1), (B) course of mean FEV1 after bronchodilation (both expressed as
percentages of predicted normal values), and (C) course of the mean postbronchodilator FEV1 (expressed in litres) during 6 months of treatment
with either fluticasone propionate (closed symbols) or placebo (open symbols).
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Bronchial inflammation
Bronchial biopsy specimens were analysed for the presence of
inflammatory cells characterised by cell surface molecules
and/or cytoplasmic proteins.
Patients with COPD were compared with asymptomatic
smoking controls. Inflammation was analysed separately in
the bronchial epithelium and 100 µm deep into the lamina
propria. None of the marker molecules was significantly
increased or decreased in the patients with COPD compared
with asymptomatic smoking control subjects. There was,
however, less CD3 detectable in the lamina propria in patients
with COPD than in the control group (table 4).
The effects of 6 months of treatment with FP or placebo
were then analysed (table 5). Compared with the placebo
group, FP treatment resulted in only a marginal reduction in
the indices of inflammation. Compared with baseline, CD8
was markedly decreased in the lamina propria of both groups.
In the FP treated group substantial reductions in MBP and
CD68 were seen in the lamina propria, while tryptase levels in
the epithelium were markedly decreased after FP treatment.
Other markers of inflammation were not affected, or only
slightly, by the treatment.
DISCUSSION
Patients with mild to moderate COPD who were hyperrespon-
sive and who continued smoking were treated with FP (500 µg
twice daily) for 6 months in a double blind, placebo controlled
study. Analysis of the methacholine dose-response curves
showed neither PC20 nor any other indices of BHR changed as
a result of FP treatment. We have previously shown that the
same dose of FP in patients with asthma with a similar degree
of BHR resulted in a rightward shift in the methacholine
dose-response curve.27 Studies in patients with COPD in which
PC20 was determined have shown that inhaled steroid
treatment had no effect on BHR.28–30 To our knowledge, this is
the first time that additional indices of BHR (reactivity,
plateau, and EC50) have also been shown not to be affected by
steroid treatment.
There was, however, a significant reduction in the decline in
both prebronchodilator and postbronchodilator FEV1 %
predicted (fig 4). Our results are supported by a recent study
by Paggiaro et al31 which showed that treatment of COPD
patients with FP (500 µg twice daily for 6 months) resulted in
improvement in FEV1 and FVC. The FP treated patients had
less frequent and less severe exacerbations. Clinical symptoms
improved significantly and sputum production decreased.
Markers of inflammation were not analysed.
Treatment for 3 years with inhaled budesonide of subjects
with mild COPD who continued smoking in the EUROSCOP
study showed an improvement in FEV1 of 17 ml/year
compared with a decline of 81 ml/year in the placebo group
during the first 6 months of the study.5 6 31 32 A similar
treatment period with FP (ISOLDE) resulted in a significant
reduction in the fall in FEV1.
33 The rate of decline in FEV1 in the
group that received placebo was markedly higher than that of
the steroid treated group over the initial 6 months of
treatment, which is comparable with our findings. In contrast,
in the Copenhagen City Lung Study long term treatment with
inhaled steroids had no effect on decline in lung function in
patients with mild to moderate irreversible airflow
limitation.6 In a recent study patients with COPD were treated
with triamcinolone for 3 years.7 A subgroup of the patients
was hyperreactive. In this subgroup the rate of decline in lung
function did not slow down when evaluated over the entire 3
year study period, but over the initial 6 months triamcinolone
had a beneficial effect on the rate of decline in FEV1 compared
with placebo. This is in line with our results which showed no
decline in FEV1 in the FP treated group while in the placebo
group FEV1 decreased significantly. The decline in FEV1 was
Figure 5 Course of (A) mean MEF50 and (B) mean MEF25 expressed as percentages of predicted values during 6 months of treatment with
either fluticasone propionate (closed symbols) or placebo (open symbols).
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Table 4 Baseline scores of inflammatory markers in epithelium and lamina propria of biopsy specimens taken from the
central airways of smoking patients with COPD and healthy smoking control subjects
Marker
Epithelium Lamina propria
Patients with COPD Healthy smoking controls Patients with COPD Healthy smoking controls
CD3 0.72 (0.10–4.52) 0.63 (0.24–0.93) 0.36 (0.04–5.71) 0.74 (0.61–1.19)
CD4 1.07 (0.14–4.00) 0.94 (0.40–2.00) 0.74 (0.07–9.00) 0.64 (0.27–1.63)
CD8 0.08 (0.03–0.60) 0.05 (0.02–0.09) 0.04 (0.03–0.42) 0.04 (0.01–0.13)
CD25 0.22 (0.03–3.28) 0.10 (0.03–0.22) 0.15 (0.03–2.39) 0.12 (0.04–0.26)
MBP 0.12 (0.03–5.27) 0.03 (0.01–0.67) 0.38 (0.00–6.45) 0.25 (0.01–5.13)
EG2 0.12 (0.01–1.79) 0.12 (0.01–0.55) 0.25 (0.03–0.68) 0.46 (0.14–8.01)
CD15 3.43 (0.08–17.4) 3.39 (0.68–8.96) 0.62 (0.14–4.73) 0.81 (0.01–1.40)
CD68 1.53 (0.24–11.4) 1.09 (0.46–1.98) 2.49 (0.44–20.10) 2.95 (1.13–4.74)
CD1a 0.12 (0.04–0.45) 0.08 (0.03–0.18) 0.14 (0.04–0.35) 0.07 (0.02–0.12)
Tryptase 0.14 (0.03–0.63) 0.10 (0.05–0.29) 1.30 (0.12–4.03) 1.23 (0.20–2.49)
Data are expressed as median (range) ratios of immunostained areas and field measurement which consisted of the total area of either the epithelium or
the lamina propria. Statistical analysis by Mann-Whitney U test after log transformation.
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most marked during the first 2 months of treatment and lev-
elled off thereafter. The initial rapid decline in patients receiv-
ing placebo may have resulted from the withdrawal of
steroids. Steroids were withdrawn at least 6 weeks before the
actual treatment period, which should have been ample time
to overcome a steroid weaning effect. A more likely
explanation for our findings may be that BHR itself causes a
decline in lung function in the absence of steroids. The benefi-
cial effect of steroid treatment in this group of patients with
COPD prevents a decline in FEV1 and keeps it constant.
It is unlikely that the treatment period of 6 months was too
short to achieve a detectable response. Based on the results of
other studies including EUROSCOP, the effects of inhaled
steroid treatment should have been achieved during this time
period.5 6 31 32 It is therefore unlikely that a longer period of
treatment with FP would have resulted in an increase in FEV1.
On the other hand, a meta-analysis of three studies published
between 1983 and 1996 showed a significant beneficial effect
of inhaled corticosteroids over placebo on the course of the
prebronchodilator FEV1 during 2 years of treatment.
34
From our analysis of the MEFV curves, we hypothesise that
the anatomical location of the anti-inflammatory effect of
inhaled steroids is in the smaller airways. Significant changes
were observed in MEF50 and MEF25. In contrast to other
studies,31 we found no effect on FVC and PEF. This discrepancy
can be attributed to differences in patient selection criteria.
Although MEF50 and MEF25 are less accurate parameters of
expiratory flow, the significance and consistency of this find-
ing indicate that the effect of FP on lung function is most
probably caused by an effect on the small airways rather than
by an effect on the larger airways.
Bronchial biopsy specimens were taken from the central
airways. Eosinophils are important in the inflammatory proc-
ess of asthma and correlate with BHR.35 We found eosinophils
to be present also in the inflammatory infiltrate in COPD at a
comparable level to that in asymptomatic smokers. It is likely
that smoking and other mechanisms that recruit neutrophils
into the airways in COPD cause a degree of eosinophil
influx.36 Recent findings show that eosinophilic airway
inflammation is common in patients with stable moderate and
severe COPD.11 In our study no significant differences in
changes in cellular indices were detected between the
treatment groups. The CD8+ lymphocytes were markedly
decreased in the lamina propria of both the FP and placebo
groups. Others have reported that CD8+ cells appear to be
relatively unresponsive to steroids,37 38 so the decreased level in
the FP treated group should not simply be attributed to treat-
ment with inhaled steroids. In the placebo group an increase
in eosinophils was detected which coincided with the decrease
in CD8+ cells. The persistent inflammation may be the cause
of the accelerated decline in FEV1 in this group of patients. We
were not able to detect a treatment effect on eosinophil counts
in the epithelium or the subepithelium. These results are also
reflected by the absence of a treatment effect on eosinophil
numbers in bronchial washings and bronchoalveolar lavage
fluid (data not shown).
Overall, this study shows that treatment with FP has a
positive effect on the indices of airflow limitation in COPD
patients with BHR. In contrast, indices of hyperresponsiveness
were not affected, while inflammation was only marginally
reduced. Our results suggest that COPD patients with BHR
benefit from treatment with inhaled steroids.
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